SCHEMBL31535210

SCHEMBL31535210

CCOC(=O)c1cc(F)c(Br)c(C(F)(F)F)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 3/20 0.46
▸ CA1 P00915 3/20 0.46
▸ CA2 P00918 3/20 0.46
▸ CA7 P43166 3/20 0.46
▸ CA9 Q16790 3/20 0.46
▸ CA14 Q9ULX7 3/20 0.46
▸ NOTUM Q6P988 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ PTPN11 Q06124 1/20 0.41
▸ HDAC3 O15379 1/20 0.39
▸ HDAC4 P56524 1/20 0.39
▸ HDAC1 Q13547 1/20 0.39
▸ HDAC6 Q9UBN7 1/20 0.39
▸ ESR1 P03372 1/20 0.39
▸ ESR2 Q92731 1/20 0.39
▸ KDM4E B2RXH2 2/20 0.38
▸ PTPN2 P17706 2/20 0.38
▸ HPGD P15428 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15570471 0.86 CA12 (0.56) CA12CA1CA2CA7CA9
SCHEMBL31535188 0.81 ALDH1A1 (0.46) CA12CA1CA2CA7CA9
SCHEMBL31535403 0.80 CA12 (0.44) CA12CA1CA2CA7CA9
SCHEMBL23826266 0.80 CA12 (0.53) CA12CA1CA2CA7CA9
SCHEMBL31439040 0.79 CA12 (0.53) CA12CA1CA2CA7CA9
SCHEMBL2543756 0.79 CA12 (0.53) CA12CA1CA2CA7CA9
SCHEMBL29219446 0.79 CA12 (0.53) CA12CA1CA2CA7CA9
SCHEMBL989378 0.79 NOTUM (0.55) CA12CA1CA2CA7CA9
SCHEMBL20702976 0.78 KIF11 (0.49) NOTUMALDH1A1HDAC1HDAC6HPGD
SCHEMBL671602 0.77 NOTUM (0.71) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122212-A1 NOVEL COMPOUNDS SITRYX THERAPEUTICS LIMITED (GB) 2025-04-17 — — US disclosed
WO-2025078808-A1 NOVEL COMPOUNDS SITRYX THERAPEUTICS LIMITED (GB) 2025-04-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122212-A1 NOVEL COMPOUNDS CYP11B1, CYP11B2, UGT1A1 CA12 416/4885CA1 1755/4885CA2 3686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback